港股异动 | 亚盛医药-B(6855.HK)涨6.09% 治疗神经母细胞瘤新药获美国授予儿童罕见病资格认证
格隆汇3月23日丨亚盛医药-B(6855.HK)涨6.09%,报17.78港元,总市值46亿港元。该公司3月22日公布,其在研原创新药MDM2-p53抑制剂APG——115(alrizomadlin),获得美国食品和药监局(FDA)授予的儿童罕见病资格认证(Rare Pediatric Disease,RPD),用于治疗神经母细胞瘤。APG-115是亚盛医药自主研发的一种口服、高选择性的MDM2-p53抑制剂,对MDM2具有 高度结合亲和力,通过阻断细胞凋亡通路关键蛋白MDM2-p53相互作用,从而恢复p53肿瘤抑制活性。目前,APG-115已经在体外和体内神经母细胞瘤模型中证明了单药治疗的抗肿瘤活性,该作用机制的明确,为该药物治疗神经母细胞瘤的临床探索提供了良好的基础。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.